Seres Therapeutics, Inc. - Common Stock (MCRB)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 11, 2026Investment Snapshot
- Trading 186% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 4.2% — below-average profitability
Seres Therapeutics, Inc. - Common Stock (MCRB) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $74 million . Key value metrics: P/E ratio 66.0, P/B ratio 2.79, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Seres Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Seres Therapeutics, Inc. - Common Stock (MCRB) is currently trading 186% above its Graham Number of $2.69, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 66.0x.
On financial health, MCRB shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 4.2% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 4.15.
StockPik's composite Value Score for MCRB is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MCRB shows earnings growing at 4,088%.